The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
Dr. Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr. Mark J. O'Connor, Prof. Charlie Gourley, Dr. Judith Balmaña, Prof. Sibylle Loibl
DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).
Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Dr. Mark J. O’Connor
Senior Scientist
AstraZeneca
United Kingdom (UK)
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain
Prof. Sibylle Loibl
Medical Oncologist
German Breast Group GmbH
Germany
Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Dr. Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Mark J. O’Connor
Senior Scientist
AstraZeneca
United Kingdom (UK)
Dr. Mark J. O’Connor has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Research
United Kingdom (UK)
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain
Dr. Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Sibylle Loibl
Medical Oncologist
German Breast Group GmbH
Germany
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| min | Sep 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.
A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.
Other programmes of interest
Other programmes developed by Dr. Violeta Serra
Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Other programmes developed by Prof. Jonathan A. Ledermann
Other programmes developed by Prof. Eric Pujade-Lauraine
Other programmes developed by Prof. Simon Boulton
Other programmes developed by Prof. Charlie Gourley
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Other programmes developed by Dr. Judith Balmaña
Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain